Table 2.
Comparison of clinical findings between symptomatic and asymptomatic groups
| Symptomatic group | Asymptomatic group |
||
|---|---|---|---|
| n = 165 (%) | n = 47 (%) | p value | |
| Age (years) | |||
| Median (range) | 49 (21–82) | 64 (38–89) | < 0.001 |
| Sex | 0.046 | ||
| Male | 84 (50.9) | 32 (68.1) | |
| Female | 81 (49.1) | 15 (31.9) | |
| Comorbidities | |||
| Ischemic heart disease | 7 (4.2) | 3 (6.4) | 0.700 |
| Liver cirrhosis | 0 (0.0) | 2 (4.3) | 0.048 |
| Diabetes mellitus | 8 (3.8) | 7 (14.9) | 0.026 |
| CKD with dialysis | 0 (0.0) | 1 (2.1) | 0.220 |
| NSAIDs | 6 (3.6) | 1 (2.1) | 0.874 |
| Acid secretion inhibitor | 25 (15.2) | 12 (25.5) | 0.126 |
| Gastric mucosa | 0.001 | ||
| No atrophy | 124 (75.2) | 21 (44.7) | |
| Atrophy | 41 (24.8) | 26 (55.3) | |
| Location | 0.386 | ||
| Upper third | 57 (34.5) | 17 (36.2) | |
| Middle third | 72 (43.6) | 24 (51.1) | |
| Lower third | 36 (21.8) | 6 (12.8) | |
| Circumference | 0.163 | ||
| Anterior wall | 15 (9.1) | 10 (21.3) | |
| Posterior wall | 28 (17.0) | 6 (12.8) | |
| Greater curvature | 97 (58.8) | 26 (55.3) | |
| Lesser curvature | 25 (15.2) | 5 (10.6) | |
| Mucosa of penetrating area | 0.038 | ||
| Atrophy | 28 (17.0) | 15 (31.9) | |
| No atrophy | 137 (83.0) | 32 (68.1) | |
| Edema, erythema, erosion | 0.429 | ||
| Positive | 130 (78.8) | 34 (72.3) | |
| Negative | 35 (21.2) | 13 (27.7) | |
CKD; chronic kidney disease, NSAIDs; non-steroidal anti-inflammatory drugs
Pearson’s chi-squared test, Mann-Whitney U test